Carisma is developing CT-0508 to target HER2-positive solid tumors. While its expression in normal tissues is low, HER2 is highly expressed in a wide range of solid tumors and plays an active role in both malignant transformation and tumor aggressiveness by promoting cancer cell proliferation, invasion and metastasis.
CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-Macrophage). In pre-clinical studies Carisma’s CAR-Macrophage cell therapies have demonstrated the ability to traffic into the tumor, phagocytose and kill cancer cells, warm-up the tumor microenvironment, and attract and activate cells of the adaptive immune system, delivering a lasting attack against the cancer.
Carisma Therapeutic scientific leaders discuss the latest findings from the CT-0508 clinical trial; immunotherapy leveraging CAR-macrophages in patients with HER2 overexpressing solid tumors. The landmark study of CT-0508 is open for enrollment and is the first of the engineered myeloid cell platform, which has applicability across hard-to-treat cancers and other serious illnesses.
CT-0508 is the first CAR-Macrophage cell therapy to enter clinical trials. Preclinical trials showed that the treatment has the potential to overcome the key challenges faced by other cell therapies in treating solid tumors.
The clinical study centers on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers do not have approved HER2-targeted therapies or who do not respond to treatment.
We are currently recruiting patients at:
Carisma has initiated a clinical study for CT-0508 in combination with Pembrolizumab. The goal of this study is to assess the potential synergy between CAR-Macrophages and anti-PD1 therapy to deliver additional benefit to patients. Carisma is also developing a CAR-Monocyte therapy (CT-0525) with a 1 day processing time and plans to file an IND in 2023.
For more on CT-0508 and our clinical trials, visit our patient clinical trial website.Clinical Trials
To learn more about our other offerings, visit our Pipeline page.Our Pipeline